These results were consistent with those of a previous study indicating that, although the MET kinase domain mutation, D1228V, can induce tumor resistance to type I MET-TKIs through impaired drug binding, the sensitivity to type II MET-TKIs is maintained (Bahcall et al., 2016). This evidence concerns the gene MET and neoplasm.